900,000 Shares in Myomo, Inc. (NYSEAMERICAN:MYO) Purchased by Soleus Capital Management L.P.

Soleus Capital Management L.P. bought a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 900,000 shares of the company's stock, valued at approximately $5,796,000. Soleus Capital Management L.P. owned about 2.98% of Myomo at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. AIGH Capital Management LLC lifted its stake in Myomo by 21.7% in the 4th quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company's stock valued at $21,777,000 after purchasing an additional 602,719 shares during the last quarter. Portolan Capital Management LLC bought a new position in shares of Myomo in the 4th quarter valued at $2,446,000. Manatuck Hill Partners LLC acquired a new stake in shares of Myomo during the 4th quarter valued at $1,582,000. Thompson Siegel & Walmsley LLC bought a new stake in Myomo during the 4th quarter worth $1,288,000. Finally, Aristides Capital LLC bought a new stake in Myomo during the 4th quarter worth $1,288,000. Institutional investors and hedge funds own 44.99% of the company's stock.

Analysts Set New Price Targets

MYO has been the topic of several research reports. HC Wainwright boosted their price target on Myomo from $7.50 to $9.50 and gave the stock a "buy" rating in a report on Wednesday, March 12th. Ascendiant Capital Markets raised their price target on shares of Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, March 17th. Alliance Global Partners reiterated a "buy" rating on shares of Myomo in a report on Tuesday, March 11th. Finally, Craig Hallum decreased their price objective on Myomo from $11.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Myomo currently has a consensus rating of "Buy" and a consensus target price of $9.50.

Myomo Trading Down 0.3%

Shares of MYO stock traded down $0.01 during mid-day trading on Thursday, hitting $3.21. The company's stock had a trading volume of 449,635 shares, compared to its average volume of 377,014. Myomo, Inc. has a 52 week low of $2.76 and a 52 week high of $7.17. The stock's fifty day simple moving average is $4.48. The company has a market cap of $97.10 million, a P/E ratio of -13.96 and a beta of 1.68.

Insiders Place Their Bets

In other Myomo news, insider Harry Kovelman sold 30,000 shares of Myomo stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.50, for a total value of $165,000.00. Following the completion of the sale, the insider now directly owns 97,973 shares of the company's stock, valued at approximately $538,851.50. The trade was a 23.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Micah Mitchell sold 48,000 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the completion of the sale, the insider now owns 140,572 shares of the company's stock, valued at approximately $725,351.52. This represents a 25.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders acquired 126,167 shares of company stock worth $427,093. 4.54% of the stock is owned by corporate insiders.

Myomo Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.